A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Rasha Kaddoura, Wafer Dabdoob, Khalid Ahmed, Mohamed A. Yassin
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
Topics & Concepts
MedicineMyeloid leukemiaTyrosine-kinase inhibitorTyrosine kinaseAdverse effectPulmonary hypertensionIntensive care medicineHeart failurePharmacologyInternal medicineCancerReceptorChronic Myeloid Leukemia TreatmentsChemotherapy-induced cardiotoxicity and mitigationSynthesis of Tetrazole Derivatives